Meeting
2019 ASCO Annual Meeting
Targeting the p300/CBP interactome through blockage of the CH1-domain triggers tumor regression in AR-positive and AR-negative xenograft models of castration-resistant prostate cancer (CRPC).
Authors
Valentino Cattori
Inthera Bioscience AG, Waedenswil, Switzerland
Valentino Cattori , Bernd Hentsch , Ulrich Kessler
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics and Tumor Biology (Nonimmuno)
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
New Targets and New Technologies (non-IO)
Citation
J Clin Oncol 37, 2019 (suppl; abstr 3105)
DOI
10.1200/JCO.2019.37.15_suppl.3105
Abstract #
3105
Poster Bd #
97
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Characterisation of CCS1477: A novel small molecule inhibitor of p300/CBP for the treatment of castration resistant prostate cancer.
First Author: Neil Pegg
Poster
2014 Genitourinary Cancers Symposium
Anticancer activity of the selective CYP17A1 inhibitor, VT-464, in preclinical models of castrate-resistant prostate cancer.
First Author: Paul Toren
Poster
2015 Genitourinary Cancers Symposium
Dual targeting of the androgen receptor and hypoxia-inducible factor-1α pathways to synergistically inhibit castrate-resistant prostate cancer.
First Author: William Douglas Figg
Poster
2014 Genitourinary Cancers Symposium
Molecular characterization of circulating tumor cells (CTCs) of patients with neuroendocrine prostate cancer (NEPC).
First Author: Himisha Beltran